Your AI-Trained Oncology Knowledge Connection!
The combination of sentinel lymph node mapping and use of uterine intraoperative restrictive frozen section in patients with low-grade endometrial cancer can reduce the rate of complete lymphadenectomy without reducing the detection of lymphatic metastasis.
Loss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.
According to a recent study, the use of oral birth control pills has prevented 200,000 cases of endometrial cancer over the last 10 years.
The addition of bevacizumab to carboplatin/paclitaxel chemotherapy increases progression-free survival in advanced/recurrent endometrial cancer patients.
The purpose of this paper is to provide a review of site-specific treatment options that involve the targeting of angiogenesis in gynecologic malignancies.
Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study.
Women with metabolic syndrome who are age 65 or older have an increased risk of endometrial cancer, according to the results of a new study.
An analysis of a large number of women suggested that those who use bisphosphonates, a bone medication used to treat osteoporosis and other bone loss diseases, have a reduced risk of endometrial cancer.
Researchers are estimating that about 3.6% of new cancer cases in 2012 in adults may be attributed to a high BMI, equating to about 481,000 new cancer cases.
The University of North Carolina has multiple posters accepted to the Gynecologic Oncology General Poster Session at this year’s ASCO meeting. Let’s take a virtual walk through several of these abstracts.
In this interview we discuss the diagnosis and treatment of endometrial cancer, a gynecologic cancer that forms in the tissue lining the uterus.
The Society of Gynecologic Oncology (SGO) recently issued two new clinical practice statements recommending genetic testing for all women with endometrial and ovarian cancers, regardless of family history.
As advances in treatment strategies continue to focus on individualization of therapy, the identification of disease subsets is crucial to strategizing optimal therapeutic approaches.
In this review, the results and limitations of studies concerning adjuvant radiation therapy and chemotherapy for endometrial cancer will be discussed, focusing on evidence that can help to guide treatment decisions.
Future directions, including nomograms, multi-modality approaches, and more individualized patient care based on genomic profiles, may help to tailor each endometrial cancer patient’s therapy to her individual risk.
Using easy-to-obtain risk factors for breast, ovarian, and endometrial cancers, researchers have come up with models that can predict an individual woman’s absolute risk for developing each type of cancer.
The data on HE4 as a prognosticator in both ovarian and endometrial cancer constitute, at most, an interesting observation, but most likely they are simply a reflection of total tumor burden. There are certainly not enough data to justify making major treatment decisions in ovarian or endometrial cancer on the basis of absolute marker levels. Proteomics and genomics seem more likely to make a difference in this area.
While a prominent role for HE4 in these areas remains to be determined, this thorough review of HE4 demonstrates that the biomarker is complementary to, and occasionally more useful than, the widely used CA 125 in the management of gynecologic malignancies.
In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.
Women diagnosed with endometrial cancer at age 50 or younger had a fourfold increased risk for a subsequent colorectal cancer diagnosis, according to a historical cohort study published recently in the Journal of Clinical Oncology.
Coffee is emerging as a protective agent against a number of diseases, including cancer. A study published last week shows that women who drank more than four cups of coffee per day cut their risk of endometrial cancer by 25% compared with those who drank less than one cup per day.
Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.
The European Society of Gynaecological Oncology (ESGO) biennial meeting is taking place in Milan, Italy, and will run from September 11-14, 2011.
Physicians must engage and educate patients about significant risk for cardiovascular disease.
